MENLO PARK, Calif., Dec. 15 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, announced today the award of U.S. patent 7,592,021 for a new bioadhesive drug delivery system that enables enhanced release of drugs through the human body's mucous membranes. This needle-free option uses gels for drug delivery and allows for a much longer release time compared to alternatives such as sprays or liquids.
Transmucosal delivery is an effective means to introduce drugs across the mucous membrane to the systemic circulation, avoiding the gastrointestinal tract and "first pass liver metabolism," which can result in only a small proportion of a drug reaching the desired targets in the body. The ease of transmucosal administration, by nebulizers or bottles, for example, often improves patient compliance compared to other forms of drug delivery. The sustained and enhanced release of therapeutic and preventive treatments enabled by SRI's bioadhesive drug delivery invention can significantly improve effectiveness and outcomes.
"This needle-free system can be used for drug delivery in any environment, even in locations where sterile medical supplies are unavailable," said Gita Shankar, Ph.D., director of formulations R&D at SRI and an inventor of the system. "Offering this option to patients can increase access to safe, effective medical care for a wide variety of conditions."
SRI's patented formulation is a two-component polymeric solution: one is responsive to pH and the other to temperature. On mixing and application to the physiological site, the two components form an adhesive gel that attaches to the mucosa, creating a platform for drug release.
Choice of application site varies depending on a variety of factors, including the duration and frequency of drug administration, and the desirability of controlled release. SRI's transmucosal drug delivery sy
|SOURCE SRI International|
Copyright©2009 PR Newswire.
All rights reserved